• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Monte Rosa Therapeutics (GLUE), What Is Behind The Fresh Attention?

    Simply Wall St·09/04/2026 14:32:12
    Listen to the news

    Monte Rosa Therapeutics (GLUE) has drawn fresh attention after dosing the first patient in its MODeFIRe-1 Phase 2 trial of MRT-2359 with apalutamide in metastatic castration-resistant prostate cancer with AR mutations.

    The fresh MODeFIRe-1 trial news arrives after a mixed stretch for Monte Rosa Therapeutics, with the share price down 10.57% over the past 30 days and 12.16% over 90 days. However, a very large 1-year total shareholder return of 192.87% and 3-year total shareholder return of 139.67% signal that long term momentum has been strong despite recent pressure.

    Spot 21 high quality undiscovered gems that, like Monte Rosa Therapeutics, are building early clinical momentum in specialized areas before most investors are paying close attention.

    Bulls point to Monte Rosa Therapeutics’ broad molecular glue pipeline and strong multi year shareholder returns, while bears focus on ongoing losses and recent share price weakness. Which side does the current valuation lean toward as the trial risk ramps up?

    Preferred Price-to-Sales Multiple of 42.7x: Is it justified?

    Monte Rosa Therapeutics most recent close at $14.38 values the business on a P/S ratio of 42.7x, which is well above both peers and the broader US biotech industry.

    The P/S ratio compares a company’s market value with its revenue. For a clinical stage biotech like Monte Rosa Therapeutics, investors often focus on this multiple because there is no profit yet and revenue is still tied to early partnerships and milestones rather than commercial products.

    Analysts currently expect Monte Rosa Therapeutics’ revenue to grow 27.2% per year, which is faster than both the US market and the 20% high growth threshold used in the forecasts. The stock’s P/S of 42.7x is described as expensive compared to the US biotechs industry average of 13.2x and also expensive against the peer average of 7.5x. It is also flagged as expensive against an estimated fair P/S ratio of 0x, which points to a valuation level that could need to adjust closer to that fair ratio if expectations change.

    This leaves Monte Rosa Therapeutics trading on a premium multiple to its sector and peer group, with the fair ratio signal pointing to a far lower level that the market could move toward if sentiment on growth or trial outcomes weakens.

    Explore the SWS fair ratio for Monte Rosa Therapeutics

    Result: Price-to-Sales of 42.7x (OVERVALUED)

    However, the story for Monte Rosa Therapeutics could shift quickly if MRT-2359 trial data underwhelms or if ongoing net losses of $161.1 million widen further.

    Find out about the key risks to this Monte Rosa Therapeutics narrative.

    Next Steps

    Given this mixed picture around Monte Rosa Therapeutics, it makes sense to move quickly and test the data against your own expectations and risk tolerance. You can weigh both the concerns and the potential rewards in one place by reviewing the 2 key rewards and 5 important warning signs

    Looking for more investment ideas beyond Monte Rosa Therapeutics?

    If you stop with Monte Rosa Therapeutics, you risk missing other opportunities that fit your style even better. Use the Simply Wall Street Screener to put fresh ideas on your radar.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.